Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.14 --0%
EPS Growth %: -31.3%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: -31.3%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman lowers Mattel rating to Sell on macro and execution risks; shares dip
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
- Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
